Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2009

01-01-2009 | Thoracic Oncology

Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients

Authors: Michael C. Cheung, MD, Kara Hamilton, MS, Recinda Sherman, BS, Margaret M. Byrne, PhD, Dao M. Nguyen, MD, Dido Franceschi, MD, Leonidas G. Koniaris, MD

Published in: Annals of Surgical Oncology | Issue 1/2009

Login to get access

Abstract

Background

Studies suggest that institutional case volume and teaching status significantly affect patient survival. We sought to compare outcomes of surgical resection for lung cancer at teaching facilities (TF) and at high-volume centers (HVC).

Methods

Patients undergoing lung cancer resection with curative intent were examined using a linked dataset from 1998 to 2002 between the Florida Cancer Data System and the Florida Agency for Health Care Administration.

Results

A total of 13,469 patients were analyzed and outcomes adjusted for comorbidities. Median survival time (MST) was superior for patients treated at TF versus nonteaching facilities (NTF) (47.1 versus 40.5 months, P < 0.001). Mortality rates at NTF were higher at 30 days (2.6% versus 1.1%, P < 0.001), 90 days (6.8% versus 3.8%, P < 0.001), and at 5 years (63.9% versus 59.2%, P = 0.005). Similarly, MST was superior in the cohort treated at HVC versus low-volume center (LVC) (45.1 versus 39.8 months, P < 0.001). Mortality was observed to be higher in LVC than HVC at 30 days (2.7% versus 1.6%, P < 0.001), 90 days (7.5% versus 4.0%, P < 0.001), and at 5 years (63.5% versus 59.3%, P = 0.002). Significant preoperative, independent predictors of survival include age, sex, smoking status, and the existence of certain comorbidities. Treatment at a TF or HVC were independent predictors of better outcome. Race, use of chemotherapy or radiation did not affect outcomes.

Conclusion

Surgical treatment for lung cancer at TF or HVC results in significantly better short- and long-term patient outcomes.
Literature
1.
2.
Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res 2007; 27:2823–7PubMed
3.
4.
Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979; 301:1364–9CrossRefPubMed
5.
Luft HS. The relation between surgical volume and mortality: an exploration of causal factors and alternative models. Med Care 1980; 18:940–59CrossRefPubMed
6.
Begg CB, Cramer LD, Hoskins WJ, et al Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280:1747–51CrossRefPubMed
7.
8.
Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007; 141:105–14CrossRefPubMed
9.
Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345:181–8CrossRefPubMed
10.
Hannan EL, Radzyner M, Rubin D, et al. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6–15CrossRefPubMed
11.
Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 2007; 245:952–8CrossRefPubMedPubMedCentral
12.
Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg 2001; 234:370–82; discussion 382–3CrossRefPubMedPubMedCentral
13.
Knipp BS, Deeb GM, Prager RL, et al. A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States. Surgery 2007; 142:524–8CrossRefPubMed
14.
Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161–77SCrossRef
15.
Meguid RA, Brooke BS, Chang DC, et al. Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 2008; 85:1015–24; discussion 1024–5CrossRefPubMed
16.
Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992; 101:1332–7CrossRefPubMed
17.
Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg 2001; 234:641–51CrossRefPubMedPubMedCentral
18.
Freixinet JL, Julia-Serda G, Rodriguez PM, et al. Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spanish multicenter study of 2994 cases. Eur J Cardiothorac Surg 2006; 29:20–5CrossRefPubMed
19.
Keagy BA, Lores ME, Starek PJ, et al. Elective pulmonary lobectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1985; 40:349–52CrossRefPubMed
20.
Nagasaki F, Flehinger BJ, Martini N. Complications of surgery in the treatment of carcinoma of the lung. Chest 1982; 82:25–9CrossRefPubMed
21.
Wahi R, McMurtrey MJ, DeCaro LF, et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 1989; 48:33–7CrossRefPubMed
22.
BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89–108
23.
Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123:105–14SCrossRef
24.
Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351–60CrossRefPubMed
25.
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719–27CrossRefPubMed
26.
Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713–21CrossRefPubMed
27.
Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453–61CrossRefPubMed
28.
Strauss GMHJE, Maddaus MA, Johnstone DW, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S)
29.
Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589–97CrossRefPubMed
30.
Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology 2007; 12:320–5CrossRefPubMed
31.
32.
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S):7008
33.
Gutierrez JC, Kassira N, Salloum RM, et al. Surgery for rectal cancer performed at teaching hospitals improves survival and preserves continence. J Gastrointest Surg 2007; 11:1441–8; discussion 1448–50CrossRefPubMed
34.
Perez EA, Gutierrez JC, Jin X, et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 2007; 11:114–25CrossRefPubMed
35.
Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623–9CrossRefPubMed
36.
Hodgson N, Koniaris LG, Livingstone AS, et al. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005; 19:1610–2CrossRefPubMed
37.
Perez EA, Koniaris LG, Snell SE, et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31:1022–30CrossRefPubMed
38.
Chen CS, Liu TC, Lin HC, et al. Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study. Breast Cancer Res Treat 2008; 110(2):349–56CrossRefPubMed
39.
Lin CC, Lin HC. Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgery 2008; 143:343–51CrossRefPubMed
40.
McKay A, You I, Bigam D, et al. Impact of surgeon training on outcomes after resective hepatic surgery. Ann Surg Oncol 2008
41.
Wen HC, Tang CH, Lin HC, et al. Association between surgeon and hospital volume in coronary artery bypass graft surgery outcomes: a population-based study. Ann Thorac Surg 2006; 81:835–42CrossRefPubMed
42.
Xirasagar S, Lien YC, Lin HC, et al. Procedure volume of gastric cancer resections versus 5-year survival. Eur J Surg Oncol 2008; 34:23–9CrossRefPubMed
Metadata
Title
Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients
Authors
Michael C. Cheung, MD
Kara Hamilton, MS
Recinda Sherman, BS
Margaret M. Byrne, PhD
Dao M. Nguyen, MD
Dido Franceschi, MD
Leonidas G. Koniaris, MD
Publication date
01-01-2009
Publisher
Springer New York
Published in
Annals of Surgical Oncology / Issue 1/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0025-9

Other articles of this Issue 1/2009

Annals of Surgical Oncology 1/2009 Go to the issue

Laboratory and Translational Research

High Expression of PRL-3 can Promote Growth of Gastric Cancer and Exhibits a Poor Prognostic Impact on Patients

Gastrointestinal Oncology

Attempted Salvage Resection for Recurrent Gastric or Gastroesophageal Cancer

Thoracic Oncology

Improving Outcomes with Lung Cancer Surgery: Selective Referral or Quality Improvement?

Hepatobiliary and Pancreatic Tumors

Expression and Clinical Significance of Cell Cycle Regulatory Proteins in Gallbladder and Extrahepatic Bile Duct Cancer

Gynecologic Oncology

Matched-Case Comparison for the Role of Surgery in FIGO Stage Ib1–IIa Squamous Cell Carcinoma of Cervix and Suspicious Para-Aortic Lymph Node Metastasis

Breast Oncology

In Favor of Axillary Lymph Node Dissection: The Need for a Pragmatic View